Pre-made Ubamatamab benchmark antibody ( Whole mAb, anti-MUC16;CD3E therapeutic antibody, Anti-CA125;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Ubamatamab (formerly REGN 4018),?a human bispecific antibody targeted against MUC16?(on tumour cells) and CD3 (on T cells), is being developed by Regeneron Pharmaceuticals for the treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer.
| Products Name (INN Index) | Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Ubamatamab |
| Target | MUC16,CD3E |
| Format | Bispecific Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G4;G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Fallopian tube cancer,Ovarian cancer,Peritoneal cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MUC16,CD3E |
| Package |
